KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Asset Writedowns and Impairment (2023 - 2026)

Biocryst Pharmaceuticals filings provide 3 years of Asset Writedowns and Impairment readings, the most recent being -$71000.0 for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 94.78% to -$71000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $985000.0, a N/A change, with the full-year FY2025 number at $985000.0, changed N/A from a year prior.
  • Asset Writedowns and Impairment hit -$71000.0 in Q4 2025 for Biocryst Pharmaceuticals, down from $30000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.4 million in Q3 2024 to a low of -$1.4 million in Q4 2024.
  • Median Asset Writedowns and Impairment over the past 3 years was $30000.0 (2025), compared with a mean of $230272.7.
  • Biggest five-year swings in Asset Writedowns and Impairment: plummeted 203.73% in 2024 and later soared 81600.0% in 2025.
  • Biocryst Pharmaceuticals' Asset Writedowns and Impairment stood at $1.3 million in 2023, then plummeted by 203.73% to -$1.4 million in 2024, then soared by 94.78% to -$71000.0 in 2025.
  • The last three reported values for Asset Writedowns and Impairment were -$71000.0 (Q4 2025), $30000.0 (Q3 2025), and $817000.0 (Q2 2025) per Business Quant data.